Raymond James Financial
TCRT icon

Raymond James Financial’s Alaunos Therapeutics TCRT Stock Holding History

Raymond James Financial’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-99
Closed -$480 – 6596
2025
Q2 		$480 Buy
+99
New +$298 ﹤0.01% 6675

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Raymond James Financial's TCRT Position: Q3 2025 in Review

Raymond James Financial sold out of Alaunos Therapeutics (TCRT) in Q3 2025, closing a stake of 99 shares — an estimated $480 sold.

Raymond James Financial first reported a position in TCRT in Q2 2025 and held it in 1 quarter. The position peaked at $480 in Q2 2025. 26 funds tracked by Wall St. Rank hold TCRT as of Q3 2025.

  • Raymond James Financial reported no remaining Alaunos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 99 Alaunos Therapeutics shares in Q3 2025, an estimated $480.
  • Raymond James Financial first reported a position in Alaunos Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Alaunos Therapeutics position peaked at $480 in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.